Week in Review: Shanghai Pharma Bids in Cardinal China's $1.5 Billion Auction

Deals and Financings Shanghai Pharma and FountainVest Partners, a China PE fund, submitted second-round bids for Cardinal China's $1.5 billion drug distribution operations; China Biologic Products, a Beijing plasma company, will acquire an 80% interest in TianXinFu ( Beijing ) Medical Appliance in an all-stock deal worth $536 million; CASI Pharma raised $23.3 million in a private placement to support is US-China operations; Suzhou 's Innovent Biologics will use a Harbour Biomed's H2L2 transgenic mouse platform to discover new mAbs, which will add to the company's 13 mAbs already in development; Gentris®, a US genomic biomarkers company, signed a MOU to form a biomarker collaboration with the Shanghai Institutes of Preventative Medicine; Government and Regulatory China 's State Council issued a directive aimed at speeding up China 's drug/device approval process, including using foreign trial data for approvals, most of which were previously announced;   Trials and Approvals   Samsung BioLogics, a Korean biologic CMO, received US FDA approval to produce an antibody drug substance at its second biologics plant; Generon of Shanghai forged a Special Protocol Assessment with the US FDA for the design of a second Phase III trial of its lead candidate, a neutropenia candidate.    Stock symbols: (SHA: 601607) (NYSE: CAH) (NSD: CBPO) (NSDQ: CASI) (KRX: 207940) Share this with colleagues: // //